Can-Fite BioPharma Ltd.
CANF · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | 0.03 | 0.05 |
| FCF Yield | -64.63% | -90.04% | -64.85% | -50.02% |
| EV / EBITDA | -0.87 | -0.63 | -1.36 | -1.21 |
| Quality | ||||
| ROIC | -113.33% | -102.14% | -146.81% | -72.85% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.97 | 1.11 | 1.06 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.94% | -4.50% | 2.01% | -25.12% |
| Free Cash Flow Growth | 9.48% | 21.91% | -9.53% | 18.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.58 | 0.52 | 0.29 | 0.33 |
| Interest Coverage | -580.71 | -585.36 | -631.04 | -713.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 41.70 | 38.32 | 21.18 | 20.54 |